The Double Helix and the Research Triangle
I welcome the opportunity to share with you some of the questions that have been raised in the Congress by the increasing commercial investments in biotechnology at universities. Although closer cooperation between universities and private companies is seen generally in Congress as desirable, particularly as a means of shortening the time between the discovery and the commercialization of a product, arrangements involving biotechnology research have received special attention because of the uniqueness and power associated with genetic engineering. Before discussing some of the concerns that have been voiced, I would like to briefly describe why biotechnology research is seen as needing to be more sensitively handled than other areas of research have been in the past.
KeywordsDouble Helix Human Application Genetic Engineering Technique Precise Guideline Foreign Corporation
Unable to display preview. Download preview PDF.
- 1.Office of Technology Assessment, Commercial Biotechnology: An International Analysis ,U.S. Government Printing Office, Washington DC (Jan. 1984).Google Scholar
- 3.Correspondence from Elmer Statz, Comptroller General of the United States, to the Honorable Albert Gore, Jr., Chairman of the Investigations and Oversight Subcommittee, Committee on Science and Technology, U.S. House of Representatives (March 1981).Google Scholar
- 4.National Science Foundation, Outlook for Science and Technology: The Next Five Years ,U.S. Government Printing Office, Washington DC (Nov. 1983).Google Scholar
- 5.U.S. Congress, Committee on Science and Technology, Investigations and Oversight Subcommittee, Draft Staff Paper, 98th Congress, 1st Sess. (1983).Google Scholar